News | Radiopharmaceuticals and Tracers | August 28, 2023

Strategic collaboration signed to support the development of radiopharmaceuticals in the fight against cancer

Strategic collaboration signed to support the development of radiopharmaceuticals in the fight against cancer

August 28, 2023 — TerraPower Isotopes and PanTera, the Belgian joint venture created by SCK CEN and IBA, announced that they have signed a strategic collaboration to increase the global availability of actinium-225 (225Ac), a radioisotope that has the potential to treat a large variety of cancer indications. The companies will work together to increase near-term production of 225Ac[1] to support ongoing clinical trials and to ensure the large-scale supply of the radioisotope in the long term, addressing growing global demand. 

This collaboration will not have any immediate financial impact but has the potential to bring substantial revenues in the future to PanTera and, indirectly, to its two shareholders SCK CEN and IBA, a listed company on the Brussels stock exchange. 

Under this collaboration, both companies will use TerraPower Isotope’s natural decay method based on thorium-229 (229Th) and PanTera’s "Gamma route" based on the Rhodotron and radium-226 to produce 225Ac. 

225Ac is a promising alpha emitter for use in Targeted Alpha Therapy (TAT). A series of molecules that are currently under research, combined with 225Ac through further manufacturing, have the potential to treat a variety of cancers, targeting solid tumors, metastases, and systemic cancers such as leukemia. There are several clinical studies currently in progress, ranging from preclinical development through to phase 3 clinical trials. Whilst there is high demand, there is a scarcity of 225Ac. The collaboration between PanTera and TerraPower Isotopes is seeking to address this supply issue and support the clinical development of 225Ac based drugs as a potential treatment option for cancer. 

"We are excited to join forces with TerraPower Isotopes to increase the market availability of 225Ac. While continuing to prepare our unique technology for large-scale production of 225Ac, as from 2024 we will also offer the radioisotope to drug developers for their research and clinical trials, as well as to physicians for compassionate use. This volume would be equivalent to 50% of today’s supply and would underpin the wider development of these targeted alpha therapy radiopharmaceuticals as an effective treatment modality for cancer", commented Sven Van den Berghe, PanTera’s Chief Executive Officer. 

Scott Claunch, President of TerraPower Isotopes, added: "Consistent with TerraPower’s vision of developing innovative solutions to help fight disease using nuclear science, TerraPower Isotopes is thrilled to secure this collaboration with PanTera. Demand for 225Ac is expected to increase as more radiopharmaceutical treatments using 225Ac are developed to treat a variety of different types of cancers. This collaboration will help us supply this valuable material to the pharmaceutical industry and meet the growing global demand."  

For more information: www.terrapower.com 

 

Related Radioisotope Content 

NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones   

NorthStar Medical Radioisotopes Announces Supply Agreement with Aktis Oncology, Inc. for Alpha-Emitting Therapeutic Radioisotope Actinium-225 (Ac-225)     

NorthStar Medical Radioisotopes and Convergent Therapeutics Announce Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)       

Update on HFR Reactor Outage – Medical Isotope Supply Returning to Normal       

Update on Unplanned Outage of the HFR Reactor       

SNMMI Issues Alert That HFR Outage Will Impact Isotope Supply       

NorthStar Medical Radioisotopes Advances Focus on Therapeutic and Specialized SPECT Radiopharmaceuticals       

How Nuclear Fusion is Revolutionizing Medical Isotope Production       

FDA Approves Additional Molybdenum-99 (Mo-99) Filling Lines at NorthStar Medical Radioisotopes       

Medical Isotope Industry Opposes Export of Highly Enriched Uranium for IRE       

IBA and NorthStar Medical Radioisotopes Expand Collaboration to Enable Global Availability of Tc-99m   

 


Related Content

News | Radiation Oncology

May 10, 2024 — Mariana Oncology, a fully integrated biotechnology company pioneering a new era of radiopharmaceutical ...

Time May 10, 2024
arrow
News | Radiation Oncology

May 10, 2024 — Insurance expansions under the Affordable Care Act (ACA) were linked with an increase in patients ...

Time May 10, 2024
arrow
News | Treatment Planning

May 6, 2024 — Elekta announced the acquisition of Philips Healthcare’s Pinnacle Treatment Planning System (TPS) patent ...

Time May 06, 2024
arrow
Feature | Radiology Business | By Melinda Taschetta-Millane

One on One interviews with radiology trailblazers and historic FDA clearances made the top-read list for April. Take a ...

Time May 03, 2024
arrow
Feature | Radiation Dose Management | By Christine Book

Advances in the growing radiation dose management market are continually helping those who administer treatment to focus ...

Time May 03, 2024
arrow
News | Artificial Intelligence

May 2, 2024 — Radformation, Inc., a leader in automation solutions for cancer care, announced today that it has acquired ...

Time May 02, 2024
arrow
News | Prostate Cancer

May 2, 2024 — GT Medical Technologies, Inc. (GT MedTech), a medical device company with the mission of improving the ...

Time May 02, 2024
arrow
News | Proton Therapy

April 29, 2024 — Koneksa, a healthcare technology company pioneering evidence-based digital biomarkers, announced today ...

Time April 29, 2024
arrow
News | FDA

April 29, 2024 — The U.S. Food and Drug Administration (FDA) announced Elekta Instrument AB is recalling Disposable ...

Time April 29, 2024
arrow
News | Radiation Dose Management

April 25, 2024 — BIOTRONIK, a leading global medical technology company specializing in innovative cardiovascular and ...

Time April 25, 2024
arrow
Subscribe Now